Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30
Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250(4988):1684-1689. doi:10.1126/science.2270482
Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. doi:10.1126/science.7545954
Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265 (5181):2088-2090. doi:10.1126/science.8091231
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975. doi:10. 1001/jama.2010.1237
Tutt ANJ, Garber JE, Kaufman B, et al; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1– OR BRCA2-mutated breast cancer. N Engl J Med. 2021; 384(25):2394-2405. doi:10.1056/NEJMoa2105215
Geyer CE Jr, Garber JE, Gelber RD, et al; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495-2505. doi:10.1056/ NEJMoa1810858
DiSilvestro P, Banerjee S, Colombo N, et al; SOLO1 Investigators. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609-617. doi:10.1200/JCO.22.01549
Kurian AW, Abrahamse P, Furgal A, et al. Germline genetic testing after cancer diagnosis. JAMA. 2023;330(1):43-51. doi:10.1001/jama.2023. 9526
Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Population frequency of germline BRCA1/2 mutations. J Clin Oncol. 2016;34(34): 4183-4185. doi:10.1200/JCO.2016.67.0554
Childers KK, Maggard-Gibbons M, Macinko J, Childers CP. National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer. JAMA Oncol. 2018;4(6):876-879. doi:10.1001/ jamaoncol.2018.0340
Thakker S, Loeb S, Giri VN, Bjurlin MA, Matulewicz RS. Attitudes, perceptions, and use of cancer-based genetic testing among healthy US adults and those with prostate or breast/ovarian cancer. UrolPract. 2023;10(1):26-32. doi:10.1097/ UPJ.0000000000000352
Daly MB. The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns. 2009;18(1):42-48. doi:10.1007/s10897-008-9183-y
Rauscher EA, Dean M. “I’ve just never gotten around to doing it”: men’s approaches to managing BRCA-related cancer risks. Patient Educ Couns. 2018;101(2):340-345. doi:10.1016/j.pec.2017.07.015
Liede A, Metcalfe K, Hanna D, et al. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet. 2000;67(6):1494-1504. doi:10. 1086/316907
Loeb S, Massey P, Leader AE, et al. Gaps in public awareness about BRCA and genetic testing in prostate cancer: social media landscape analysis. JMIR Cancer. 2021;7(3):e27063. doi:10.2196/27063
Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019;322 (7):652-665. doi:10.1001/jama.2019.10987
Park SY, Kim Y, Kim S, Katapodi MC. Informational needs of individuals from families harboring BRCA pathogenic variants: a systematic review and content analysis. Genet Med. 2023;25 (4):100001. doi:10.1016/j.gim.2022.100001
National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic (version 3.2023). Accessed May 4, 2023. physician_gls/pdf/genetics_bop.pdf
Sessa C, Balmaña J, Bober SL, et al; ESMO Guidelines Committee. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(1):33-47. doi:10. 1016/j.annonc.2022.10.004
Leone AG, Trapani D, Schabath MB, et al. Cancer in transgender and gender-diverse persons: a review. JAMA Oncol. 2023;9(4):556-563. doi:10. 1001/jamaoncol.2022.7173
Mandelker D, Marra A, Zheng-Lin B, et al. Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol. 2023; 41(33):5151-5162. doi:10.1200/JCO.23.00561
Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing. J Natl Cancer Inst. 2018;110(8):855-862. doi:10.1093/ jnci/djy106
Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. Germline and somatic mutations in prostate cancer for the clinician. J Natl ComprCancNetw. 2019;17(5):515-521. doi:10.6004/jnccn.2019.7307
Lowery MA, Wong W, Jordan EJ, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst. 2018;110(10):1067-1074. doi:10.1093/ jnci/djy024
Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375 (5):443-453. doi:10.1056/NEJMoa1603144
Hussain M, Mateo J, Fizazi K, et al; PROfound Trial Investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345-2357. doi:10. 1056/NEJMoa2022485
Fizazi K, Piulats JM, Reaume MN, et al; TRITON3 Investigators. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732. doi:10.1056/NEJMoa2214676
Ndugga-Kabuye MK, Issaka RB. Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European. Fam Cancer. 2019;18(4):465-469. doi:10.1007/s10689-019-00144-6
Cheng HH, Klemfuss N, Montgomery B, et al. A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling. Prostate. 2016;76(14):1303-1311. doi:10.1002/pros.23219
Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825-835. doi:10.1001/jama.2017.11137
Schrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016;2(1): 104-111. doi:10.1001/jamaoncol.2015.5208
Scheinberg T, Goodwin A, Ip E, et al. Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract. 2021;17(2): e204-e216. doi:10.1200/OP.20.00399
Cheng HH, Sokolova AO, Gulati R, et al. Internet-based germline genetic testing for men with metastatic prostate cancer. JCO Precis Oncol. 2023;7:e2200104. doi:10.1200/PO.22.00104
Loeb S, Cheng HH, Leader A, et al. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): a randomized controlled trial of a pretest patient-driven webtool vs genetic counseling for prostate cancer germline testing. Contemp Clin Trials. 2022;119:106821. doi:10.1016/j.cct.2022.106821
Oliva L, Lozano R, Llácer C, et al. Risk prediction tools available for germline BRCA1/2 mutations underperform in prostate cancer patients. EurUrol Oncol. 2021;4(2):315-318. doi:10.1016/j.euo.2019. 06.019
Lindor NM, Johnson KJ, Harvey H, et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer. 2010;9(4):495-502. doi:10. 1007/s10689-010-9348-3
Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-431. doi:10.1136/jmg.2007. 056556
Nyberg T, Frost D, Barrowdale D, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020; 77(1):24-35. doi:10.1016/j.eururo.2019.08.025
Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529-1541. doi:10.1200/JCO.21.02112
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, etal. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.J Med Genet. 2005: 42(9):711-719. doi:10.1136/jmg.2004.028829
Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23): 1811-1814. doi:10.1093/jnci/djm203
Leongamornlert D, Mahmud N, Tymrakiewicz M, etal; UKGPCS Collaborators. Germline BRCA1 mutations increase prostate cancer risk. BrJCancer. 2012;106(10): 1697-1701. doi:10.1038/bjc.2012.146
Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68(2): 186-193. doi:10.1016/j.eururo.2014.10.022
Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31 (14):1748-1757. doi:10.1200/JCO.2012.43.1882
Page EC, Bancroft EK, Brook MN, et al; IMPACT Study Collaborators. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76(6):831-842. doi:10.1016/j.eururo. 2019.08.019
Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part i: prostate cancer screening. J Urol. 2023;210 (1):46-53. doi:10.1097/JU.0000000000003491
Sawhney MS, Calderwood AH, Thosani NC, et al; Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. GastrointestEndosc. 2022;95(5):817-826. doi:10. 1016/j.gie.2021.12.001
Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159(1):358-362. doi:10.1053/j.gastro.2020. 03.088
Goggins M, Overbeek KA, Brand R, et al; International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17. doi:10.1136/ gutjnl-2019-319352
National Comprehensive Cancer Network. Prostate cancer early detection (version 1.2023). Accessed May 4, 2024. https://www.nccn.org/ professionals/physician_gls/pdf/prostate_detection. Pdf
The IMPACT study: identification of men with a genetic predisposition to prostate . Accessed June 21, 2024.
Men at high genetic risk for prostate . Accessed June 21, 2024.
Prostate screening study using MRI in BRCA . Accessed June 21, 2024.
Prostate screening for men with inherited risk of developing aggressive prostate cancer, PATROL . Accessed June 21, 2024.
Prostate cancer genetic risk evaluation and screening study, . Accessed June 21, 2024. https://clinicaltrials.gov/ study/NCT05129605
MRI screening in men at high risk of developing prostate . Accessed June 21, 2024. NCT05608694
Dbouk M, Katona BW, Brand RE, et al. The multicenter cancer of pancreas screening study: impact on stage and survival. J Clin Oncol. 2022;40(28):3257-3266. doi:10.1200/JCO.22.00298
CAPS5: the Cancer of the Pancreas Screening–5 . Accessed June 21, 2024. https://clinicaltrials.gov/ study/NCT02000089
PCEDP: Pancreatic Cancer Early Detection . Accessed June 21, 2024.
Preliminary evaluation of screening for pancreatic cancer in patients with inherited genetic . Accessed June 21, 2024.
A pancreatic cancer screening study in hereditary high risk . Accessed June 21, 2024. https://clinicaltrials.gov/ study/NCT03250078
PRECEDE: pancreatic cancer early detection . Accessed June 21, 2024. NCT04970056
Pancreas scan: pancreatic cancer screening for at-risk . Accessed June 21, 2024. NCT05006131
Pilot study of pancreatic cancer . Accessed June 21, 2024.
A registry for BRCA mutation carriers with pancreatic ductal . Accessed June 21, 2024.
Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401-2409. doi:10.1001/jama. 2018.6228
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223-262. doi:10.1038/ajg. 2014.435
Katona BW, Long JM, Ahmad NA, et al. EUS-based pancreatic cancer surveillance in BRCA1/BRCA2/PALB2/ATM carriers without a family history of pancreatic cancer. Cancer Prev Res (Phila) . 2021;14(11):1033-1040. doi:10.1158/1940-6207. CAPR-21-0161
Wang L, Domchek SM, Kochman ML, Katona BW. Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations. Genes Cancer. 2022;13: 49-51. doi:10.18632/genesandcancer.223
Kogekar N, Diaz KE, Weinberg AD, Lucas AL. Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: a meta-analysis. Pancreatology. 2020;20(8):1739-1746. doi:10.1016/ j.pan.2020.10.025
Overbeek KA, Levink IJM, Koopmann BDM, et al; Dutch Familial Pancreatic Cancer Surveillance Study Group. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71 (6):1152-1160. doi:10.1136/gutjnl-2020-323611
Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis. Gastroenterology. 2018; 155(2):490-500.e2. doi:10.1053/j.gastro.2018.04.025
Overbeek KA, Goggins MG, Dbouk M, et al; International Cancer of the Pancreas Screening Consortium. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology.
Saldia A, Olson SH, Nunes P, et al. Outcome of pancreatic cancer surveillance among high-risk individuals tested for germline mutations in BRCA1 and BRCA2. Cancer Prev Res (Phila). 2019;12(9): 599-608. doi:10.1158/1940-6207.CAPR-18-0272
Lucas AL, Fu Y, Labiner AJ, Dimaio CJ, Sethi A, Kastrinos F. Frequent abnormal pancreas imaging in patients with pathogenic ATM, BRCA1, BRCA2, and PALB2 breast cancer susceptibility variants. Clin Gastroenterol Hepatol. 2023;21(10):2686-2688.e2. doi:10.1016/j.cgh.2022.08.040
American Cancer Society. Key statistics for breast cancer in men. Accessed May 4, 2023.
Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors. Semin Oncol. 2017; 44(4):267-272. doi:10.1053/j.seminoncol.2017.11.002
Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 2011;126(3):771-778. doi:10.1007/s10549-010-1195-2
Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018;18(1):179. doi:10.1186/s12885-018-4098-y
Silvestri V, Barrowdale D, Mulligan AM, et al; kConFab Investigators; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); EMBRACE. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18(1):15. doi:10. 1186/s13058-016-0671-y
Gaddam S, Heller SL, Babb JS, Gao Y. Male breast cancer risk assessment and screening recommendations in high-risk men who undergo genetic counseling and multigene panel testing. Clin Breast Cancer. 2021;21(1):e74-e79. doi:10.1016/ j.clbc.2020.07.014
Marino MA, Gucalp A, Leithner D, et al. Mammographic screening in male patients at high risk for breast cancer: is it worth it? Breast Cancer Res Treat. 2019;177(3):705-711. doi:10.1007/ s10549-019-05338-1
Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8(6):871-878. doi:10.1001/jamaoncol.2022.0476
Usui Y, Taniyama Y, Endo M, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med. 2023;388(13):1181-1190. doi:10.1056/NEJMoa2211807
Buckley KH, Niccum BA, Maxwell KN, Katona BW. Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers. Cancers (Basel). 2022;14 (23):5953. doi:10.3390/cancers14235953
Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol. 2015;172 (6):1498-1506. doi:10.1111/bjd.13626
Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121(2):269-275. doi:10.1002/cncr.29041
Phelan CM, Iqbal J, Lynch HT, et al; Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014;110 (2):530-534. doi:10.1038/bjc.2013.741
Suchy J, Cybulski C, Górski B, et al. BRCA1 mutations and colorectal cancer in Poland. Fam Cancer. 2010;9(4):541-544. doi:10.1007/s10689-010-9378-x
Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA clinical practice update on colorectal and pancreatic cancer risk and screening in BRCA1 and BRCA2 carriers: commentary. Gastroenterology. 2020;159(2):760-764. doi:10.1053/j.gastro.2020. 03.086
Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362): 362ps17. doi:10.1126/scitranslmed.aaf9246
Pujade-Lauraine E, Ledermann JA, Selle F, et al; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274-1284. doi:10.1016/S1470-2045(17)30469-2
Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375 (22):2154-2164. doi:10.1056/NEJMoa161131
Coleman RL, Oza AM, Lorusso D, et al; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-1961. doi:10.1016/ S0140-6736(17)32440-6
Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772-782. doi:10.1016/j.annonc. 2023.06.009
Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291-303. doi:10.1016/ S0140-6736(23)01055-3
Clarke Noel W, Armstrong Andrew J, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043. doi:10. 1056/EVIDoa2200043
Chi KN, Rathkopf D, Smith MR, et al; MAGNITUDE Principal Investigators. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(18):3339-3351. doi:10.1200/JCO.22.01649
Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094-1108. doi:10.1016/ S1470-2045(23)00382-0
Pomerantz MM, Spisák S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123(18):3532-3539. doi:10.1002/cncr.30808
Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol. 2016;69(6):992-995. doi:10.1016/j.eururo.2015.11.022
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387
Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO Trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40(34): 3929-3939. doi:10.1200/JCO.21.01604
Reiss KA, Mick R, O’Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22): 2497-2505. doi:10.1200/JCO.21.00003
O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020; 38(13):1378-1388. doi:10.1200/JCO.19.02931
Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122 (3):333-339. doi:10.1038/s41416-019-0582-7
Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39-47. doi:10.1016/j. ejca.2023.01.031
Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558-566. doi:10.1093/annonc/ mdz012
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533. doi:10.1056/NEJMoa1706450
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379 (8):753-763. doi:10.1056/NEJMoa1802905
Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591. doi:10.1038/s41588-019-0379-x
Kerminen S, Martin AR, Koskela J, et al. Geographic variation and bias in the polygenic scores of complex diseases and traits in Finland. Am J Hum Genet. 2019;104(6):1169-1181. doi:10.1016/j. ajhg.2019.05.001
Barnes DR, Silvestri V, Leslie G, et al; GEMO Study Collaborators; EMBRACE Collaborators; KConFab Investigators; HEBON Investigators; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores. J Natl Cancer Inst. 2022; 114(1):109-122. doi:10.1093/jnci/djab147
Paller CJ, Antonarakis ES, Beer TM, et al; PCCTC Germline Genetics Working Group. Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium. Clin Genitourin Cancer. 2019;17(4):275-282.e1. doi:10.1016/j.clgc. 2019.04.013
Loeb S, Li R, Sanchez Nolasco T, et al. Barriers and facilitators of germline genetic evaluation for prostate cancer. Prostate. 2021;81(11):754-764. doi:10.1002/pros.24172
Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020;38(24): 2798-2811. doi:10.1200/JCO.20.00046
Fine E, Knoll MA, Maslow BL. Fertility considerations for reproductive-aged carriers of deleterious BRCA mutations: a call for early intervention. JCO Oncol Pract. 2022;18(3):165-168. doi:10.1200/OP.21.00389
Dean M, Campbell-Salome G, Rauscher EA. Engaging men with BRCA-related cancer risks: practical advice for BRCA risk management from male stakeholders. Am J Mens Health. 2020;14(3): 1557988320924932. doi:10.1177/1557988320924932
